DURECT Corporation  

(Public, NASDAQ:DRRX)   Watch this stock  
Find more results for DRRX
1.36
+0.02 (1.49%)
After Hours: 1.36 0.00 (0.00%)
May 2, 4:40PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.31 - 1.40
52 week 0.99 - 3.42
Open 1.35
Vol / Avg. 472,857.00/561,756.00
Mkt cap 175.34M
P/E     -
Div/yield     -
EPS -0.19
Shares 134.70M
Beta 1.00
Inst. own 46%
May 5, 2016
Q1 2016 DURECT Corp Earnings Call - 4:30PM EDT - Add to calendar
May 5, 2016
Q1 2016 DURECT Corp Earnings Release - 4:00PM EDT - Add to calendar
Feb 29, 2016
Q4 2015 DURECT Corp Earnings Call - Webcast
Feb 29, 2016
Q4 2015 DURECT Corp Earnings Release
Feb 8, 2016
DURECT Corp at Biotechnology Industry Organization (BIO) CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin -113.12% -118.51%
Operating margin -103.14% -108.05%
EBITD margin - -105.83%
Return on average assets -49.31% -46.80%
Return on average equity -146.09% -135.71%
Employees 106 -
CDP Score - -

Address

10240 Bubb Rd
CUPERTINO, CA 95014-4166
United States - Map
+1-408-7771417 (Phone)
+1-408-7773577 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Durect Corporation is a biopharmaceutical company with research and development programs. The Company's products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic. The Company's ALZET product line consists of miniature, implantable osmotic pumps and accessories used for experimental research in mice, rats and other laboratory animals. The Company also manufactures and sells osmotic pumps used in laboratory research and design; and develops and manufactures a range of standard and custom biodegradable polymers and excipients for pharmaceutical and medical device clients for use as raw materials in their products.

Officers and directors

Felix Theeuwes DSc Chairman, Chief Scientific Officer
Age: 77
Bio & Compensation  - Reuters
James E. Brown DVM President, Chief Executive Officer and Director
Age: 58
Bio & Compensation  - Reuters
Matthew J. Hogan Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Judy R. Joice Senior Vice President - Operations and Corporate Quality Assurance
Age: 58
Bio & Compensation  - Reuters
David R. Hoffmann Lead Independent Director
Age: 70
Bio & Compensation  - Reuters
Simon X. Benito Independent Director
Age: 70
Bio & Compensation  - Reuters
Terrence F. Blaschke M.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Armand P. Neukermans Ph.D. Independent Director
Age: 74
Bio & Compensation  - Reuters
Jon S. Saxe Independent Director
Age: 79
Bio & Compensation  - Reuters